Osteoblasts, the bone forming cells, affect self-renewal and expansion of hematopoietic stem cells (HSCs), as well as homing of healthy hematopoietic cells and tumor cells into the bone marrow. Constitutive activation of β-catenin in osteoblasts is sufficient to alter the differentiation potential of myeloid and lymphoid progenitors and to initiate the development of acute myeloid leukemia (AML) in mice. We show here that Notch1 is the receptor mediating the leukemogenic properties of osteoblast-activated β-catenin in HSCs. Moreover, using cell-specific gene inactivation mouse models, we show that FoxO1 expression in osteoblasts is required for and mediates the leukemogenic properties of β-catenin. At the molecular level, FoxO1 interacts with β-catenin in osteoblasts to induce expression of the Notch ligand, Jagged-1. Subsequent activation of Notch signaling in long-term repopulating HSC progenitors induces the leukemogenic transformation of HSCs and ultimately leads to the development of AML. These findings identify FoxO1 expressed in osteoblasts as a factor affecting hematopoiesis and provide a molecular mechanism whereby the FoxO1/activated β-catenin interaction results in AML. These observations support the notion that the bone marrow niche is an instigator of leukemia and raise the prospect that FoxO1 oncogenic properties may occur in other tissues.
INTRODUCTION
Over the last few years, it has become increasingly apparent that stromal cells within the bone marrow microenvironment influence the fate of hematopoietic stem cells (HSC). [1] [2] [3] [4] [5] [6] [7] [8] In particular, osteoblasts, the bone-forming cells, influence HSC fate. [9] [10] [11] [12] Osteoblastic cells support and expand HSCs in vitro and increase engraftment in vivo. 13 They can both stimulate 11, 12 and limit HSC expansion, 14 promote quiescence, 3, 15, 16 initiate HSC mobilization, 17, 18 and regulate B lymphopoiesis 19, 20 and myeloproliferation. 21 They also integrate sympathetic nervous system signaling and HSC regulation. 22 In addition, mesenchymal stem cells of the osteoblast lineage affect HSC function in mouse models of myeloproliferative neoplasms 23, 24 resulting in the development of myelodysplasia (MDS) and acute myeloid leukemia (AML). 25 Osteoblastic cells also differentially regulate the progression of chronic versus acute myeloid leukemia. 26 Recent findings have extended the regulatory role of osteoblasts beyond hematopoiesis and into the initiation of hematological disease by showing that genetic alterations in osteoblasts can induce AML in mice and are associated with AML development in humans. 27 Indeed, constitutive activation of β-catenin signaling in mouse osteoblasts disrupts hematopoiesis by shifting the differentiation potential of HSC progenitors to the myeloid lineage, compromising B-lymphopoiesis and inducing anemia. As a result, granulocyte/monocyte progenitors accumulate and AML develops, which is characterized by infiltration of blood, bone marrow, spleen and liver with immature myeloid and dysplastic cells. This type of osteoblast-induced AML phenotype can be transferred to healthy mice and is associated with clonal evolution at the cytogenetic level. The pathway transmitting the leukemogenic signal of activated β-catenin in osteoblasts involves induction of Notch signaling in HSC progenitors. These observations are relevant to human disease, because β-catenin nuclear accumulation in osteoblasts and activation of Notch signaling in hematopoietic cells was detected in a population of patients with MDS, AML and AML that arose from a prior MDS.
The molecular mechanisms underlying the oncogenic function of β-catenin in osteoblasts are incompletely understood. With the goal to improve this knowledge, we sought transcription factors that could interact with β-catenin and affect its activity in osteoblasts. Among the many candidates we focused on FoxO1, a member of the FoxO family of Forkhead transcription factors, because it interacts with β-catenin in osteoblasts, as well as in other cells types, where it acts to oppose β-catenin function. [28] [29] [30] [31] At the same time, FoxO1 is required to maintain the function and immature state of leukemia-initiating cells 32 raising the possibility that, at least part of the AML-potentiating properties of FoxO1 might be due to its expression in osteoblasts in addition to its expression in hematopoietic cells. These observations led us to hypothesize that FoxO1 may also influence the leukemogenic function of constitutive active β-catenin in osteoblasts.
In testing this working hypothesis through genetic and molecular means, we observed that FoxO1 in osteoblasts does interact with β-catenin, to upregulate Notch ligand expression on osteoblasts and to subsequently induce Notch signaling in longterm repopulating HSC progenitors. This interaction leads to anemia, myeloid expansion and AML development.
MATERIALS AND METHODS Animals
FoxO1 fl/fl , α1(I)Collagen-Cre [α 1 (I)Col-Cre] and Catnb +/lox(ex3) mice have been reported. [33] [34] [35] [36] Specific deletion of Notch1 and Notch2 in hematopoietic cells was obtained by breeding Notch1 fl/fl 42 (purchased from Jax, Bar Harbor, Maine, USA; Stock# 007181) or Notch2 fl/fl mice 37 (purchased from the Jackson Laboratory, Bar Harbor, Maine, USA; Stock# 010525) with Vavcre transgenic mice 38 (purchased from the Jackson Laboratory; Stock# 008610). The comparative analysis of all histological and flow cytometry measurements was performed at 1 month of age because Ctnnb1 CAosb and Ctnnb1 CAosb ;FoxO1 osb − / − mice die between 4 and 6 weeks of age. Additional details are provided in the Supplementary Information. All the protocols and experiments were conducted according to the guidelines of the Institute of Comparative Medicine, Columbia University.
Microarray
Total RNA was extracted from primary osteoblasts isolated from mouse calvaria using Trizol reagent (Invitrogen, Norwalk, CT, USA). Microarray analysis was performed using the GeneChip 3′ IVT Express kit and mouse genome 430 2.0 array gene chips (Affymetrix, Santa Clara, CA, USA). Detailed protocol is provided in Supplementary Information.
Hematological measurements and peripheral blood morphology
Blood was collected by cardiac puncture and cell counts were performed on a FORCYTE Hematology Analyzer (Oxford Science Inc., Oxford, CT, USA). Further details are included in Supplementary Information.
Reporter constructs and luciferase assays
Mouse FoxO1, FoxO3, FoxO4 and β-catenin expression constructs were transfected in HEK293T, OB-6 or primary osteoblasts. Further details about the preparation of reporter constructs and luciferase assays are given in Supplementary Information.
Antibodies and flow-cytometry analysis
Freshly isolated bone marrow cells and spleen cells were resuspended in flow-staining buffer (PBS plus 2% FBS) and primary conjugated antibodies were added. After 30 min of incubation at 4°C, cells were washed twice before flow-cytometry analysis. Detailed staining protocol and listing of antibodies are given in Supplementary Information.
Histological analysis of murine bone, spleen and liver
Murine long bones, spleen and liver were collected from 1-month-old mice, fixed overnight in 10% neutral formalin solution, embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin (H&E). Murine bones were decalcified before paraffin embedding. Immunohistochemistry details are provided in Supplementary Information.
Bone marrow transplantation
Ctnnb1 CAosb mice, Notch1 fl/fl ;vav-cre, Notch2 fl/fl ;vav-cre and their WT control littermates were all CD45.2 congenic mice. Therefore, for transplantation experiments, donor-derived bone marrow cells were labeled with CellTrace Far Red DDAO-SE fluorescent dye (Invitrogen) according to the manufacturer's instructions. Further details are given in the Supplementary Information.
Assessment of chimerism
Engraftment efficiency in recipients was monitored by donor contribution of cells with red fluorescence in the blood, bone marrow, spleen and thymus of recipients using FACS analysis. Additional details are provided in Supplementary Information.
Statistical analysis
All data are represented as mean ± s.d. Statistical analyses were performed using a one-way ANOVA followed by Student-Newman-Keuls test and a P-value of o0.05 was considered as significant.
RESULTS

FoxO1 promotes β-catenin signaling in osteoblasts
To determine whether FoxO1 affects β-catenin signaling in osteoblasts, we examined whether the two endogenous proteins interact. FoxO1 physically associated with β-catenin in osteoblasts ( Figure 1a ). Consistent with this observation, expression of the β-catenin transcriptional targets, Axin2, Tcf1, Tcf3 and Lef1 was increased following forced expression of FoxO1 in osteoblasts ( Figure 1b ). Expression of the same β-catenin target genes was also upregulated in the bone of Ctnnb1 CAosb mice (Figure 1c ). In contrast, expression of the FoxO1 targets cyclin D1, D2, p27Kip1, Superoxide Dismutase 2 (Sod2) and Gadd45 was not affected by forced expression of β-catenin in osteoblasts ( Figure 1d ). In vivo, expression of Axin2, Tcf1, Tcf3 and Lef1 was decreased in bones from mice harboring an osteoblast-specific inactivation of FoxO1 (FoxO1 osb − / − ) as compared with wild-type (WT) littermates ( Figure 1e ). In contrast, expression of the FoxO1 targets was not altered in the bone of Ctnnb1 CAosb mice expressing the constitutively active β-catenin allele in osteoblasts ( Figure 1f ). Confirming the purity of the material used to assess gene expression in bone, expression of the blood-specific genes GlycophorinA, CD19 and CD45 was barely detectable in bone (Figures 1g-i). FoxO1 protein levels were not altered in Ctnnb1 CAosb mice ( Figure 1j ). Taken together, these observations suggest that FoxO1 and β-catenin could form a functional complex in which FoxO1 acts as a coactivator of β-catenin required for β-catenin activity.
FoxO1 induces anemia and potentiates myeloid expansion in response to activated β-catenin
To investigate whether FoxO1 synergizes with β-catenin in osteoblasts to deregulate hematopoiesis in Ctnnb1 CAosb mice, we generated mice lacking FoxO1 in osteoblasts by crossing mice harboring a floxed allele of FoxO1 with mice expressing Cre under the control of 2.3 kb of the proximal promoter of the mouse pro-α1(I)Collagen gene. 39 Before analyzing these mutant mice we verified we had deleted FoxO1 in osteoblasts but not in HSC or other cell types (Figure 2a ). The expression of Axin2, Tcf1, Tcf3 and Lef1 was normalized in the compound mutant mice confirming that removing one allele of FoxO1 had normalized β-catenin signaling in osteoblasts (Figures 2b-e ).
We reasoned that if the activating mutation of β-catenin in osteoblasts causes leukemia in a FoxO1-dependent manner then removing one FoxO1 allele should normalize hematopoiesis in Ctnnb1 CAosb mice. Consistent with this hypothesis and cell culture results presented in Figure 1 , anemia, peripheral monocytosis, neutrophilia and lymphocytopenia, features observed in Ctnnb1 CAosb mice, 27 Table 1 ).
Ctnnb1 CAosb mice are characterized by a shift in the differentiation of HSCs to the myeloid lineage at the expense of Blymphopoiesis. 27 Therefore, we examined whether haploinsufficiency at the FoxO1 locus in osteoblasts would correct deregulation of these two lineages in the bone marrow and spleen. We observed that the increase in the relative percentage of myeloid (CD11b+/Gr1+) cells seen in the Ctnnb1 CAosb bone marrow was normalized in Ctnnb1 CAosb ;FoxO1 osb +/ − mice (Figures 3a and b ). Likewise, the percentage of myeloid cells in the spleen of Ctnnb1 CAosb ;FoxO1 osb +/ − mice was similar to that of WT animals (Figures 3c and d) . The loss of typical splenic architecture, expansion of red pulp and coalescence of white pulp, observed in Ctnnb1 CAosb mice was inhibited in Ctnnb1 CAosb ; FoxO1 osb +/ − mice ( Figure 3e ).
Because monocytes and granulocytes originate from the same progenitors, we examined the hematopoietic stem and progenitor cell populations in the bone marrow. The hematopoietic stem and progenitor cell pool size, defined by the percentage of Lin-Sca+c-Kit+ (LSK) cells, is twofold greater than in WT littermates ( Figure 3f ). FoxO1 haploinsufficiency in osteoblasts of Ctnnb1 CAosb ;FoxO1 osb +/ − mice reversed the defect in LSK cells. Similarly, it prevented the increase in the LSK+/CD150+/CD48 − subset of long-term repopulating HSC progenitors (LT-HSCs) (Figures 3g and h ). In the bone marrow, within the myeloid progenitor population (Lin-Kit+Sca1 − ), alterations in the granulocyte/monocyte progenitor subset (CD34/FcgRII/III, GMP population), observed in Ctnnb1 CAosb mice, were rescued in Ctnnb1 CAosb ; FoxO1 osb +/ − mice (Figures 3i and j) . Likewise, Ctnnb1 CAosb ; FoxO1 osb +/ − mice showed normal GMP population percentage in the spleen (Figures 3k and l) .
Taken together, these findings indicate that defects in bone marrow, peripheral and spleen hematopoiesis caused by constitutive active β-catenin signaling in osteoblasts are fully rescued by removing one allele of FoxO1 from osteoblasts.
Constitutively active β-catenin acts through FoxO1 in osteoblasts to induce AML development We next asked whether FoxO1, in addition to mediating deregulation of hematopoiesis in Ctnnb1 CAosb mice, is also involved in the development of myeloid malignancy. Histological analysis showed that the cellular alterations observed in Ctnnb1 CAosb mice associated with their AML phenotype were rescued in Ctnnb1 CAosb ;FoxO1 osb +/ − animals. Specifically, monocytic and myeloid cells of the long bones, spleen and liver were similar in Ctnnb1 CAosb ;FoxO1 osb +/ − and WT mice ( is similar to other mouse AML models, which present with variable extent of leukemia blast infiltration 40 such as the AML model of human AML1/MDS1/EVI1 fusion protein. 41 In the Ctnnb1 CAosb model, limited infiltration in the liver may be due to the (Figure 4f ). Myeloperoxidase staining of immature myeloid cells in bone marrow, spleen and liver of Ctnnb1 CAosb ;FoxO1 osb +/ − mice was similar to that of WT animals, establishing that leukemogenesis did not occur in these mice (Figures 4g-i) .
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-WT Figures 5c-f ). Finally, FoxO1 haploinsufficiency in osteoblasts prevented the early lethality phenotype of Ctnnb1 CAosb mice since Ctnnb1 CAosb ; FoxO1 osb +/ − mice lived and were healthy for at least 1 year, the entire time that they were observed (Figure 5g ). Importantly, reduction of FoxO1 levels in osteoblasts of Ctnnb1 CAosb ;FoxO1 osb +/ − mice did not rescue the osteopetrotic phenotype that is observed in Ctnnb1 CAosb mice, suggesting that AML development occurs independent of osteopetrosis ( Figure 5h ). Collectively, these results indicate that the development of AML by constitutive activation of β-catenin in osteoblasts depends on FoxO1. In addition, they demonstrate an oncogenic role of FoxO1 in osteoblasts that is triggered by constitutive activation of β-catenin in the same cells and potentiates leukemogenesis.
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A β-catenin/FoxO1 interaction in osteoblasts regulates HSC function through Notch signaling Next, we sought to investigate the molecular mechanisms through which FoxO1 synergizes with β-catenin to induce AML development. We have previously shown that constitutive activation of β-catenin in osteoblasts induces AML, in part by promoting the expression of Jagged-1 in the same cells. As a result Notch signaling is activated in long-term HSC progenitors (LT-LSK cells). 27 To obtain genetic proof of this mechanism, we inactivated Notch signaling specifically in hematopoietic cells of Ctnnb1 CAosb mice by inactivating either the Notch1 or the Figure 1a ). Overall chimerism, 2 weeks after transplantation, reached 50-70% in all examined tissues ( Supplementary Figures 1b and c) . Our analysis indicated 40-50% and 67-80% chimerism within the LSK and LT-LSK populations, the Leukemia Initiating Population from Ctnnb1 CAosb mice, respectively ( Supplementary Figures 1d and e ). Far redlabeled donor cells were able to differentiate into the myeloid (CD11b+), B-lymphoid (CD19+) and erythroid (Terr 119+) lineages ( Supplementary Figures 1f-k) . Notch signaling was also assessed in LSK cells following 10 weeks of transplantation. In the transplanted Ctnnb1 CAosb mice, Notch signaling was decreased as tested by the expression of Notch transcriptional targets (Figures 6a and b ). At this time Notch1 and Notch2 recombination in the marrow and spleen of transplanted Ctnnb1 CAosb mice reached 70-90% (Figures 6c and d) . This degree of recombination along with our observation that host hematopoiesis is ablated in lethally irradiated neonate Ctnnb1 CAosb recipients suggest that the LSK cells used to assess Notch signaling are mainly derived from donor hematopoiesis.
Recipients of Notch2-deficient hematopoietic cells showed heavy infiltration of blood with blasts and dysplastic neutrophils (Figure 6e) ; their numbers ranged from 18 to 75% and 20 to 70%, respectively, within 20 days following transplantation. Transplanted mice maintained low body weight (Figure 6f) , and similar to the Ctnnb1 CAosb mice transplanted with WT bone marrow cells, died within 5 weeks following transplantation (Figure 6g ). In contrast, transplantation of Ctnnb1 CAosb neonates with Notch1deficient hematopoietic cells prevented AML development (Figure 6h ), progressively increased body weight (Figure 6i ) and rescued lethality as transplanted Ctnnb1 CAosb mice survived for at least 23 weeks (Figure 6j ), the entire time they were observed. These results indicate that activation of Notch signaling in HSCs of Ctnnb1 CAosb mice mediates the leukemogenic signal of osteoblasts and that this event is facilitated by Notch1.
In view of this observation, we asked whether β-catenin and FoxO1 act synergistically to activate Jagged-1/Notch signaling and/or whether FoxO1 in response to activated β-catenin induces a distinct pathway that deregulates HSC fate and is also required for AML development.
To distinguish between these two possibilities, we performed an unbiased approach, microarray analysis. To identify potential targets, we looked for complementary changes in the expression of secreted molecules in microarrays of Ctnnb1 CAosb and Fox-O1 osb − / − osteoblasts. The aim of this experiment was to identify FoxO1 targets and to generate compound mutant mice to examine whether β-catenin and FoxO1 synergize in vivo to regulate expression of the identified target. For these genetic epistasis experiments, we needed to know the genes that are deregulated in the FoxO1 − / − osteoblasts so that we could verify that they were not deregulated in the FoxO1+/ − osteoblasts. Microarray analysis of 12 000 genes from Ctnnb1 CAosb and 34 000 genes from FoxO1 osb − / − osteoblasts identified only one gene with opposite changes in its expression in both cell types, Jagged-1, a Notch ligand (Supplementary Table 2 ).
Further experiments confirmed the results of the microarray analysis since, Jagged-1 was upregulated in Ctnnb1 CAosb and downregulated in FoxO1 osb − / − compared with WT osteoblasts (Figure 7a ). We subsequently examined whether FoxO1 mediates the effects of constitutive activation of β-catenin in osteoblasts to increase Notch signaling in LT-LSK cells, the leukemia-initiating cells that can transfer the AML of Ctnnb1 CAosb mice to healthy animals. Similar to the reversal of LSK expansion, removal of one (g and j) , n = 6 mice per group. In (f), n = 8 mice in WT-WT, Notch2-WT transplanted groups at all indicated time points. n = 8 mice in WT-Ctnnb1 CAosb transplanted group at weeks 1, 2 and 3 and n = 3 mice at week 4. n = 8 mice in Notch2-Ctnnb1 CAosb transplanted group at weeks 1, 2 and 3 and n = 4 mice at week 4. *P o0.05 versus Notch1-Ctnnb1 CAosb transplanted group. In (i), n = 6 mice per group in WT-WT, Notch1-WT and Notch1-Ctnnb1 CAosb transplanted groups at all indicated time points. n = 6 mice in WT-Ctnnb1 CAosb transplanted group at weeks 1, 2 and 3 and n = 3 mice at week 4. *Po 0.05 versus Notch1-Ctnnb1 CAosb transplanted group. In (a and b) *P o0.05 versus WT-WT transplanted mice. Data are pooled from two independent experiments. Results are mean ± s.d. Solid arrows indicate blasts and dotted arrows indicated hypersegmented neutrorphils.
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FoxO1 allele from osteoblasts of Ctnnb1 CAosb mice reversed the increased expression of the Notch targets Hes1, Hes5, Hey1 and Hey2 specifically in the leukemia-initiating LSK+/CD150+/CD48 − subpopulation (LT-HSCs) (Figures 7b-e ). These results demonstrate that Notch signaling in hematopoietic cells mediates the leukemogenic signal of activated β-catenin in osteoblasts. They also show that FoxO1 is required for activation of the Jagged-1/Notch pathway by β-catenin in osteoblasts and for AML development.
Transcriptional control of Jagged-1 by β-catenin/FoxO1 signaling in osteoblasts The regulation of Jagged-1 expression in osteoblasts by canonical Wnt signaling and FoxO1 suggested that it might be a direct To confirm the existence of β-catenin/FoxO1 complex in the same DNA region, rechIP experiments were performed. In these assays, chromatin was first precipitated with antibodies against β-catenin, then was eluted from the beads and subjected to a second immunopurification with antibodies against FoxO1 and vice versa. As shown in Figure 7f , specific signals were observed with both combinations of sequential immunoprecipitations using primers amplifying the -2038/-1691 and -1431/-1085 region of the Jagged-1 promoter. There is no significant rechIP signal even if β-catenin alone is present at the -4317/-4015 region of the promoter showing the simultaneous presence of the two proteins at the elements located within the proximal 2 kb region of the Jagged-1 promoter (Figure 7f ). The biological importance of these sites was examined by transient transfection assays in FoxO1deficient or WT primary osteoblasts using a reporter construct containing the 4.1-kb of the Jagged-1 promoter fused to the luciferase gene (Jag1-4.1-luc). Overexpression of β-catenin/TCF-1 alone in FoxO1-deficient osteoblasts could not transactivate the Jagged-1 promoter; while re-introduction of FoxO1 induced a 5fold increase (Figure 7g ). Thus, β-catenin is able to form a complex with FoxO1 that enhances β-catenin binding and co-operatively contribute to Jagged-1 upregulation.
Taken together, these observations suggest that β-catenin activation in osteoblasts in conjunction with FoxO1 induces expression of the Notch ligand, Jagged-1, which in turn triggers downstream activation of Notch signaling in adjacent HSCs.
FoxO3 and FoxO4 compensate FoxO1 homozygous deficiency in Ctnnb1 CAosb ;FoxO1 − / − osteoblasts and lead to AML development In addition to FoxO1, osteoblasts express FoxO3 and FoxO4 and all three transcription factors are involved in the regulation of bone mass. 31, 42, 43 Based on this expression pattern and the fact that the three isoforms have redundant functions when expressed in hematopoietic cells, 44 we examined whether FoxO3 and FoxO4 can compensate for the leukemogenic function of FoxO1 in its absence. For this purpose, we generated mice expressing constitutive active β-catenin but lacking both FoxO1 alleles in osteoblasts (Ctnnb1 CAosb ;FoxO1 osb − / − mice). Ctnnb1 CAosb ; FoxO1 osb − / − mice showed deregulated hematopoiesis and the presence of blasts and dysplastic cells in the blood, marrow, spleen and liver, indicating that they had developed AML ( Supplementary Figures 2a-h) . Ctnnb1 CAosb ;FoxO1 osb − / − mice have a compound bone phenotype: they are osteopetrotic due to activation of β-catenin but also have low osteoblast numbers due to FoxO1 deficiency in osteoblasts ( Supplementary Figures 3a-c) . Bone volume was similar to that of Ctnnb1 CAosb mice, probably because the decrease in osteoclast numbers is pronounced enough to compensate for the decrease in osteoblast numbers.
To understand the mechanism of AML development, we measured Jagged-1 expression in their osteoblasts and found that it was increased in the osteoblasts of Ctnnb1 CAosb ;FoxO1 osb − / − mice, to the same level as in osteoblasts of Ctnnb1 CAosb mice ( Supplementary Figure 4a ). Dose response assays comparing the ability of FoxO1, FoxO3 and FoxO4 to activate a Jagged-1 reporter construct show that FoxO1 is a more potent activator than FoxO3 and FoxO4 with 3.5-to 10-fold activity at concentrations of 0.01-0.5 μM ( Supplementary Figure 4b) . Moreover, combination of FoxO3 and FoxO4 at equal doses of 0.06 or 0.2 μM increased Jagged-1 promoter activity to similar levels as 0.2 μM of FoxO1. Taken together, these results indicate that decreased levels of FoxO1 in Ctnnb1 CAosb ;FoxO1 osb +/ − osteoblasts prevent FoxO3 and FoxO4 from binding to the Jagged-1 promoter and upregulate Jagged-1 expression and therefore prevent AML development. Homozygous deletion of FoxO1 in Ctnnb1 CAosb ;FoxO1 osb − / − osteoblasts allows FoxO3 and FoxO4 to compensate in upregulating Jagged-1 expression by β-catenin and the AML phenotype to develop.
DISCUSSION
In this study, we identified a novel function of FoxO1 in osteoblasts as a leukemia potentiator and deciphered the molecular bases of this function. Specifically, we show that FoxO1 synergizes with activated β-catenin in osteoblasts to initiate a program of gene expression that disrupts hematopoiesis by altering HSC lineage determination, ultimately leading to AML. This entire signaling cascade, which mediates the crosstalk between osteoblasts and HSCs, is initiated by activation of canonical Wnt signaling in osteoblasts. In turn, stabilized β-catenin acts through FoxO1 to promote expression of Notch ligands in osteoblasts, leading to activation of Notch signaling in HSCs. These findings demonstrate that osteoblasts are able to produce signals that affect the fate of HSCs and simultaneously induce an oncogenic process. They also show that FoxO1, a known tumor suppressor, assumes the opposite role in osteoblasts, where it acts as a tumor inducer capable of triggering AML in response to activated β-catenin signaling. Similar to our finding that FoxO1 is pro-leukemogenic when expressed in osteoblasts, and in spite of the fact that FoxOs are primarily known as tumor suppressors, indications of a tumorigenic role for them have been previously reported in chronic and acute myeloid leukemia. High expression of FOXO3 has been associated with adverse prognosis in AMLs exhibiting normal cytogenetics. 45 Furthermore, genetic ablation of FoxO3 reduced disease burden in a mouse model of chronic myeloid leukemia. 46 Finally, activation of both FoxO1 and FoxO3 has been implicated in human AML as means of inducing myeloid block. 32 Therefore, whether it acts through osteoblasts or through leukemia blasts FoxO1 is an inducer or potent modulator of myeloid leukemia.
Our observations together with current evidence indicate that FoxO1 has different functions in activating β-catenin signaling in osteoblasts depending on the stage of osteoblast differentiation, and these distinct functions may differentially regulate normal and malignant hematopoiesis. Indeed, FoxO1 inhibits β-catenin signaling by tethering it away from its transcriptional complex 31 in osteoblast progenitors, which are implicated in normal hematopoiesis by affecting HSC lineage determination survival and proliferation, 1,2,20,47-49 HSC expansion 11, 12, 20 and quiescence, 14,50 erythroid lineage 11, 12 and B lymphopoiesis. 19, 20 In contrast, we show that FoxO1 synergizes with β-catenin in osteoblasts to induce malignant hematopoiesis and the development of AML. These observations suggest that cell differentiation along the osteoblast lineage is a complex process and that manipulating FoxO1/β-catenin signaling in the osteoblast or its progenitor can have different repercussions on hematopoiesis.
An 'osteoblastic niche' has been proposed as a specialized microenvironment, which provides a quiescent state for the maintenance of hematopoietic cell stemness. 9 Changes in it may precede and promote the initiation of genetic events by creating a pre-malignant state characterized by disruption of quiescenceinducing signals or increases in proliferating signaling. 51 Our study directly implicates osteoblasts in the development of leukemogenesis. Similarly, deletion of Dicer1 in Osterix-expressing osteoblast progenitors has been shown to induce MDS with pancytopenia and emergence of secondary leukemia. 25 These two studies address two different pathways: one that involves microRNA regulation of gene expression and one that affects expression of canonical Wnt signaling targets. Currently it is not known whether the two pathways intersect, since specific microRNAs expressed in osteoblasts and affecting hematopoiesis have not been identified. This important question needs to be addressed in the future.
The fact that Ctnnb1 CAosb mice have an osteopetrotic phenotype raised the possibility that part of the hematopoietic dysfunction may be due to narrowing of the bone marrow cavity. However, our observations demonstrate that leukemogenesis occurs independent of osteopetrosis in Ctnnb1 CAosb mice. Inactivation of one FoxO1 allele as well as pharmacological inhibition of Notch signaling 27 rescued dysfunctional hematopoiesis and leukemia in Ctnnb1 CAosb mice without affecting osteopetrosis. In support of these observations, HSC progenitors are maintained in osteopetrotic mice and osteoclasts do not affect HSC maintenance or mobilization. 52 Additionally, in contrast to the pancytopenic phenotype observed in Ctnnb1 CAosb mice, narrowing of the bone marrow cavity in osteopetrosis mouse models does not affect peripheral blood parameters. 53, 54 Thus, compromised HSCs function, leukemogenesis and mortality observed in Ctnnb1 CAosb mice occur independent of osteopetrosis.
The mechanisms through which osteoblasts affect hematopoiesis are now being elucidated. As they emerge, they suggest a variety of signals that can affect different aspects of hematopoiesis. A functional interaction between osteoblasts and HSCs that involve engagement of Notch1/Jag1 signaling promotes HSC proliferation. 11, 12 One involving non-canonical Wnt signaling maintains quiescent long-term HSCs, 55 whereas inactivation of Wnt signaling in osteoblasts disrupts stem cell quiescence, leading to a loss of self-renewal potential through a Shh-mediated pathway. 56 Recently, disruption of HIF signaling in osteoprogenitors was shown to directly modulate erythropoiesis. 57 These studies underscore the importance of understanding the entire spectrum of functions of osteoblasts in regulating HSC activity and indicate that identifying the mechanisms through which such functions occur can have implications in hematological diseases.
Targeting the hematopoietic niche is currently a new strategy for eradicating persistent and drug-resistant leukemia stem cells. [58] [59] [60] Our observations show that a new niche-specific interaction between activated β-catenin and FoxO1 which takes place in osteoblasts is sufficient to initiate a complex phenotype of disordered hematopoiesis that is reminiscent of AML in humans. In view of these data, we propose that targeting of FoxO signaling may inhibit osteoblast-induced AML or render the osteoblastic niche hostile to CML or AML cells in other models.
